瑋俊生物科技(00660.HK)與認購人訂立補充認購協議 11月30日復牌
格隆匯 11 月 27日丨瑋俊生物科技(00660.HK)發佈公告,建議“10合1”並股已獲履行,股份合併將於2020年11月27日(星期五)生效。合併股份的交易已於11月27日上午九時正開始。
由於股份合併11月27日生效,公司於11月27日與認購人訂立補充認購協議,以確認認購人已有條件同意認購的認購價,以及公司已有條件同意的認購價配發及發行認購股份將為每股認購股份0.095港元。經考慮股份合併的影響,認購人同意認購併同意由公司配發及發行的認購股份總數為464,539,191股認購股份。每股認購股份的認購價為0.095港元,較認購協議日期在聯交所所報的收市價每股合併股份0.1港元折讓約5%(經計及股份合併的影響)。
自11月27日(星期五)上午九時三十分起,公司股票在聯交所的交易已暫停,等待該公告發布。公司已向聯交所提出申請,要求自11月30日(星期一)上午九時正起恢復股份在聯交所的交易。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.